Coronary Trials
- XIENCE
XIENCE Short DAPT study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03218787?term=xience+short+dapt&rank=1
Peripheral Trials
- CONFIDENCE
A prospective, multicenter, single-arm, open label clinical study to evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT02657707
- CREST II
Carotid revascularization and medical management for asymptomatic carotid stenosis trial
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02089217
- DISRUPT PAD
Randomized study of the Shockwave Medical Peripheral Lithoplasty® System used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries (Disrupt PAD III).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02923193?term=disrupt+pad&rank=3
- ROX
A prospective, randomized, adaptive, double-blind, sham-controlled, multicenter study to evaluate the ROX Coupler in subjects with hypertension.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02895386?term=rox&draw=1&rank=4
- TRANSCEND DCB
The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects With Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral® Drug-Coated Balloon.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT03241459?term=Transcend+DCB&rank=1
- WING-IT
A Non-Randomized Study Evaluating the Use of the ReFlow Medical Wingman Catheter to Cross Chronic Total Occlusions in Infrainguinal Peripheral ArTeries. Prospective, multi-center, non-randomized single-arm study of the Wingman Catheter to cross a single infrainguinal peripheral chronic total occlusion (CTO).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03403426
- DETOUR II
A prospective, single-arm, multi-center, international, non-randomized, safety and effectiveness clinical investigation of the PQ Bypass system. The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to >15 cm long occlusions and diffuse stenosis of femoropopliteal arteries, including in-stent re-stenosis, with reference vessel diameters ranging from 5.0 – 6.7 mm.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Structural Heart Trials
- REPRISE III
REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus™ Valve System – Randomized Clinical Evaluation: To evaluate the safety and effectiveness of the Lotus™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02202434
- PARTNER 3
To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, symptomatic aortic stenosis who are at low operative risk for standard aortic valve replacement (AVR). Prospective, randomized, controlled, multi-center trial. Patients having an operative mortality < 2% (low operative risk) for surgical aortic valve replacement will be randomized 1:1 to receive either transcatheter heart valve replacement (TAVR) with the Edwards SAPIEN 3 or aortic valve replacement with a commercially available surgical bioprosthetic valve. Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 10 years.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT02675114
- EARLY TAVR
To establish the safety and effectiveness of the Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, California) Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03042104?term=early+tavr&draw=1&rank=1
- LAMPOON
Intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow tract obstruction during transcatheter mitral valve implantation.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT03015194?term=LAMPOON&rank=1
- AMPLATZER™ PFO Occluder Post-Approval Study
AMPLATZER™ PFO Occluder Post Approval Clinical Study is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder, in a post approval setting, in patients with a PFO who have had a cryptogenic stroke confirmed by a study neurologist.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03309332
- ASAP-TOO
A prospective, randomized, multi-center, global investigation to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device (including the post-implant medication regimen) with non-valvular atrial fibrillation who are deemed not suitable for anti-coagulation therapy to reduce the risk of stroke.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02928497
- WATCH-TAVR
A prospective, multicenter, randomized controlled trial, to evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
EP Trials
- ADAPT RESPONSE
Medtronic, Inc. is sponsoring the AdaptResponse study; a prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global Cardiac Resynchronization Therapy (CRT) in heart failure (HF) clinical study. The purpose of this clinical study is to test the hypothesis that market released CRT devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02205359
- ARTESIA
Prospective, randomized, parallel group, double-blind trial To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT01938248?term=artesia&draw=1&rank=1
- SMART CRT
SMART CRT is a prospective, double-blind, multicenter, international, randomized controlled trial. The primary objective is to show the benefit of SmartDelay™ in patients with a prolonged RV-LV interval.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03075215?term=smart+crt&rank=2
- PREEMPT
A global, multi-center, post-market, prospective, non-randomized study, to collect device and clinical event data to evaluate extended applications of the HeartLogic™ Heart Failure Diagnostic (HeartLogic) in a broad spectrum of heart failure (HF) patients with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Heart Failure Trials
- CHAMP HF
Observational Registry of Treatment Patterns in the U.S. Heart Failure Patients with Reduced Ejection Fraction
If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com
- CONNECT-HF
This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of 2 quality improvement (QI) initiatives compared with the usual care on heart failure (HF) outcomes and HF quality of care metrics in the year following discharge for participants hospitalized with acute HF and reduced ejection fraction (EF). All participants in the trial will be consented for longitudinal follow-up as part of the CONNECT_HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality of life (QOL) assessments, at 6 weeks and 3, 6, 12 months after discharge.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03035474?term=connect+hf&rank=1
- BEAT-HF
The purpose of this clinical trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy™ with the Barostim neo system in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or with a Cardiac Resynchronization Therapy (CRT) device.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02627196?term=beat+hf&draw=1&rank=3
- PERSPECTIVE
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Heart Failure and Preserved Ejection Fraction
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02884206?term=PERSPECTIVE&draw=1&rank=8
More Coming soon…..